Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821.

摘要: We determined the type and frequency of chromosomal aberrations in leukemic cells 478 children diagnosed with acute myeloid leukemia enrolled Pediatric Oncology Group study 8821. Of cases, 109 (22.8%) had normal karyotypes. Chromosomal abnormalities 280 patients (58.6%) were classified into subgroups: 11q23 (n = 88, 18.4%), t(8;21) 56, 11.7%), t(15;17) 55, 11.5%), inv(16)/t(16;16) 28, 5.9%), trisomy 8 alone 10, 2.1%), monosomy 7 9, 1.9%), non-Down-associated 21 7, 1.5%), rare recurrent translocations 27, 5.6%). The remaining 89 (18.6%) miscellaneous clonal abnormalities. Overall, 84.9% achieved a complete remission; 4-year event-free survival (EFS) estimate was 33.8% +/- 2.4%. Remission rates significantly higher (96.4%, P =.011) for but lower (74.5%, =.022) those t(15;17). rate all 43.5% 2.4%; an inv(16)/t(16;16), 75.0% 8.6%; karyotype, 53.8% 4.9%; t(8;21), 51.6% 7.3%; t(15;17), 39.8% 6.9%; abnormality, 32.9% 5.1%. Four-year EFS estimates (58.2% 10.9%, =.007), (45.1% 7.7%, =.014), or karyotypes (43.1% 5.0%, =. 012) than patients, (19.6% 8.0%, =.033) (23.8% 4.8%, =.0013) lower. did not differ among subgroups. Limited analysis suggested that inv(16) can be salvaged better following relapse t(8;21). Thus, may have high when treated chemotherapy alone.